Adjuvant Chemotherapy for Breast Cancer: How Presentation of Recurrence Risk Influences Decision-Making
Celia Chao, Jamie L. Studts, Troy Abell, Terence Hadley, Lynne Roetzer, Sean Dineen, Doug Lorenz, Ahmed YoussefAgha, Kelly M. McMasters
From the Division of Surgical Oncology and the Department of Medicine and Behavioral Oncology Program, James Graham Brown Cancer Center; the Departments of Psychological and Brain Sciences and the Biostatistics-Decision Science Program, University of Louisville; and the Division of Medical Oncology, Norton Healthcare, Louisville, KY; Abell Research Consulting, Ouray, CO.
Address reprint requests to Celia Chao, MD, Department of Surgery, University of Texas Medical Branch, 301 University Blvd, Route 0527, Galveston, TX 77555-0527; e-mail: email@example.com or Jamie L. Studts, PhD, James Graham Brown Cancer Center, 529 S Jackson St, Louisville, KY 40202; e-mail: firstname.lastname@example.org.
Purpose: The purpose of this study was to examine the impact of four methods of communicating survival benefits on chemotherapy decisions. We hypothesized that the four methods of communicating mathematically equivalent risk information would lead to different chemotherapy decisions.
Methods: Each participant received two hypothetical scenarios regarding their mother (a postmenopausal woman with an invasive, lymph node-negative, hormone receptor-positive breast cancer) and was asked to decide whether they would encourage their mother to take chemotherapy in addition to surgery and tamoxifen.
In the part 1, participants received one of four methods of describing the chemotherapy survival benefit: (1) relative risk reduction, (2) absolute risk reduction, (3) absolute survival benefit, or (4) number needed to treat. In part 2, each participant received all four methods. Following each decision, participants were asked to rate their confidence and confusion regarding their decision.
Results: Participants included 203 preclinical medical students. In part 1, participants who received relative risk reduction information were significantly more likely to endorse chemotherapy.
In part 2, there were no treatment decision differences when participants received all four methods of communicating survival benefits of chemotherapy.
However, receiving all four methods led to significantly higher ratings of confusion. In deciding on endorsing chemotherapy, participants understood the information best when presented with data in the absolute survival benefit format.
Conclusion: These results support the hypothesis that the method used to present information about chemotherapy influences treatment decisions. Absolute survival benefit is the most easily understood method of conveying the information regarding benefit of treatment.
Supported by the Center for Advanced Surgical Technologies (CAST) of Norton Hospital, Louisville, Kentucky and the Links for Life Foundation, Louisville, Kentucky.
Journal of Clinical Oncology, Vol 21, Issue 23 (December), 2003: 4299-4305
This is a study I am very glad to see. I have argued for years that it is all in the presentation. I have heard discussions at medical meetings where various doctors will 'complain' that their patients 'choose' chemotherapy when there is little or no benefit possible.
I have always stated that when NO alternatives are presented, people will seize what is available. And as this study points out, when relative risk, numbers taht really do not relate to the actual risk, are given, it makes informed decision making even more difficult.
The Annie Appleseed Project believes in informed decisions.
JNCI, June 2001,
Euro Fed of Cancer Societies,
Breast Cancer Res & Treatment,
DiaTech Oncology - Drug Sensitivity Assay
Medicare Contractor Establishes Reimbursement Coverage Policy for Cell Culture Assay Tests
Cancer Cell, 2/02
Reuters Health, 4/08/02
AACR News Release
In Vitro Sensitivity Increased Survival:Glioblastoma
ATP Chemosensitivity Test: Ova/BCa
Panel Says Test NOT Ready - Pts Say Yes!
Predict Response to Chemotherapy
British J Cancer, 4/02
Evidence Against Using Body-Surface Area for Dosage
Oncol Rep, 3/02
Ca Cancer J Clin, 5/04
LINK to many articles on
tumor assays, edited by
Larry Weisenthal, MD, PhD
LINK to Robert Nagourney, MD
site for chemo assays
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.